Nonalcoholic fatty liver disease (NAFLD) affects a large population with incompletely
defined mechanism (s). Here we report that Kindlin-2 is dramatically up-regulated in livers in …

Non-alcoholic fatty liver disease (NAFLD) is a common clinical disease, and its
pathogenesis is closely linked to oxidative stress and gut microbiota dysbiosis. Recently …

During the course of the COVID-19 pandemic, obesity has been shown to be an
independent risk factor for high morbidity and mortality. Obesity confers poor outcomes in …

Diabetes mellitus results from an interplay between insulin resistance and β-cell dysfunction.
Since their relative contributions to its pathogenesis are difficult to quantify, therapeutic …

Abstract Purpose of Review Nonalcoholic fatty liver disease (NAFLD) is an often
unrecognized complication of type 2 diabetes (T2DM) associated with significant economic …

Aims To compare different treatments for non‐alcoholic steatohepatitis (NASH) and to
determine an effectiveness hierarchy. Materials and Methods We conducted a systematic …

Obeticholic acid (OCA) has been examined to treat non-alcoholic steatohepatitis (NASH),
but has unsatisfactory antifibrotic effect and deficient responsive rate in recent phase III …

Background Psoriasis is observationally associated with a higher risk of non-alcoholic fatty
liver disease (NAFLD); however, the causal relationship between the two diseases remains …

Background: Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the population.
Clinical trials have questioned the role of vitamin E in the treatment of NAFLD with or without …

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are
common conditions with a rising burden. Yet there are significant management gaps …